Search | Clinical Trials Finder

Conditions: Obstructive Pulmonary Function, Restrictive Pulmonary Function
Interventions: single dose (100 mg) of ASA, single dose (162 mg) of non-enteric-coated chewable aspirin tablets; Drug
Lead sponsor: Vectura, Inc.; Industry
Eligibility: 40 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 4
States / cities: Orlando, Florida • Winter Park, Florida • Baltimore, Maryland + 1 more

Conditions: HIV-1 Infection
Interventions: Aspirin, Placebo; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 18 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 15
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 10 more

Conditions: High Risk Polycythemia Vera, High Risk Essential Thrombocythemia
Interventions: PEGASYS, Aspirin; Drug
Lead sponsor: Ronald Hoffman; Other
Eligibility: 18 Years and older
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 16
States / cities: Scottsdale, Arizona • Palo Alto, California • Washington D.C., District of Columbia + 10 more

Conditions: Metastatic Triple Negative Breast Cancer
Interventions: L-NMMA, Docetaxel, Amlodipine, Pegfilgrastim, Enteric-coated aspirin; Drug
Lead sponsor: The Methodist Hospital Research Institute; Other
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anterior Cruciate Ligament Injuries
Interventions: Opiate Sparing, Opiate Based; Drug
Lead sponsor: Campbell Clinic; Other
Eligibility: 14 Years to 85 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Skokie, Illinois • Cincinnati, Ohio • Memphis, Tennessee

Conditions: Bipolar Disorder Depression
Interventions: Minocycline, Aspirin, placebo; Drug
Lead sponsor: Laureate Institute for Brain Research, Inc.; Other
Eligibility: 18 Years to 65 Years
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 3
States / cities: Wichita, Kansas • Tulsa, Oklahoma

Conditions: Argininosuccinic Aciduria, Amino Acid Metabolism, Inborn Errors, Urea Cycle Disorders
Interventions: Sodium Phenylbutyrate, Arginine; Drug
Lead sponsor: Brendan Lee; Other
Eligibility: 5 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Cancer
Interventions: Aspirin, Placebo; Drug
Lead sponsor: Hennepin Healthcare Research Institute; Other
Eligibility: 65 Years and older
Enrollment: 14,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2024
U.S. locations: 40
States / cities: Birmingham, Alabama • Palo Alto, California • Washington D.C., District of Columbia + 32 more

Conditions: Aspirin-Sensitive Asthma With Nasal Polyps, Samter's Syndrome
Interventions: Water, Red wine, Polyphenolic Compounds; Dietary Supplement
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Aortic Valve Stenosis, Cardiovascular Diseases, Heart Valve Diseases, Ventricular Outflow Obstruction, Thrombosis
Interventions: Acetylsalicylic acid, Clopidogrel, Rivaroxaban; Drug
Lead sponsor: ECRI bv; Industry
Eligibility: 18 Years and older
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 4
States / cities: Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more

Conditions: Anesthesia, Opioid Use
Interventions: Guided mindfulness exercises, Self-administered aromatherapy, Baby aspirin, Tylenol/Acetaminophen, Pregabalin, Prednisone, Meloxicam, Prilosec, Tramadol, Voltaren, Zofran, Pepcid, Reglan, Versed, Lidocaine, Propofol, Ancef, Tranexamic Acid (TXA), Decadron, Bupivacaine hydrochloride, Toradol; Behavioral · Other · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Coronary Artery Disease
Interventions: Ticagrelor Tablets, Clopidogrel (over encapsulated) capsule, Aspirin Tablets; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 8
States / cities: Baton Rouge, Louisiana • Baltimore, Maryland • Towson, Maryland + 5 more

Conditions: Effect of Drug
Interventions: Aspirin 325mg; Drug
Lead sponsor: Hematology Oncology Associates of Central New York; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: East Syracuse, New York

Conditions: Atrial Fibrillation, Vascular Risk
Interventions: clopidogrel (SR25990C), placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 7,554 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Platelet Aggregation Inhibitors
Interventions: Aspirin; Drug
Lead sponsor: Inova Health Care Services; Other
Eligibility: 18 Years to 55 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Falls Church, Virginia

Conditions: Peripheral Arterial Disease
Interventions: Clopidogrel, Acetylsalicylic acid (ASA); Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 159 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 4
States / cities: Denver, Colorado • Davenport, Iowa • Dallas, Texas

Conditions: Cardiovascular Disease
Interventions: Active Clonidine, Placebo Clonidine, Active ASA, Placebo ASA; Drug
Lead sponsor: Hamilton Health Sciences Corporation; Other
Eligibility: 45 Years and older
Enrollment: 10,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Atrial Fibrillation, Stroke, Bleeding
Interventions: WATCHMAN FLX Pro LAAC Device; Device
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 1,857 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 86
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 78 more

Conditions: Pulmonary Embolism, Thromboembolism, Thrombosis, Venous Thrombosis, Venous Thromboembolism
Interventions: BAY 59-7939, ASA; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 3,365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 24
States / cities: Beverly Hills, California • La Jolla, California • Ventura, California + 19 more

Conditions: Hypertension
Interventions: Cardiovascular Fixed Dose Combination Pill AAR, Atorvastatin 40 mg, Ramipril 10 mg; Drug
Lead sponsor: Ferrer Internacional S.A.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 528 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 36
States / cities: Birmingham, Alabama • Los Angeles, California • Sacramento, California + 29 more

Conditions: Hypertension
Interventions: Clonidine, Nitroglycerin transdermal, Dipyridamole/ Aspirin (Aggrenox), Desmopressin (DDAVP), Sildenafil, Nifedipine, Hydralazine, Hydrochlorothiazide, Placebo, Bosentan, Diltiazem, Eplerenone, guanfacine, L-arginine, captopril, carbidopa, losartan, metoprolol tartrate, nebivolol hydrochloride, prazosin hydrochloride, tamsulosin hydrochloride, Head-up tilt., aliskiren, Local heat stress; Drug · Dietary Supplement · Other
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2017
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypertension
Interventions: Combination pill, Ramipril; Drug
Lead sponsor: Ferrer Internacional S.A.; Industry
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: New York, New York

Conditions: Renal Impairment
Interventions: Elinogrel; Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Knoxville, Tennessee

Conditions: Prevention & Control
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Aspirin, Aspirin placebo, Rivaroxaban placebo, Pantoprazole, Pantoprazole placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 27,395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 53
States / cities: Birmingham, Alabama • Mobile, Alabama • Anaheim, California + 49 more

Search by objective public record fields.

Study to Compare the Pharmacokinetics and Pharmacodynamics of ASA Powder for Oral Inhalation With Non-enteric-coated Chewable Aspirin in Adult Subjects With Obstructive or Restrictive Pulmonary Function

Modulation of Immune Activation by Aspirin

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

L-NMMA Plus Taxane Chemotherapy in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients

Reduce Opiate Exposure With ACL Surgery

Minocycline and Aspirin in the Treatment of Bipolar Depression

Arginine and Buphenyl in Patients With Argininosuccinic Aciduria (ASA), a Urea Cycle Disorder

ASPREE Cancer Endpoints Study

Mechanisms of Alcohol Sensitivity in AERD

Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)

PROUD Study - Preventing Opioid Use Disorders

A Study of the Onset and Offset of Antiplatelet Effects Comparing Ticagrelor, Clopidogrel, and Placebo With Aspirin

PFA 100 Evaluation and Reference Interval HOACNY

Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)

Pharmacodynamics and Pharmacokinetics of Aspirin Inhalation Powder With Non-Enteric-Coated Chewable Aspirin

Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities

PeriOperative ISchemic Evaluation-2 Trial

SIMPLAAFY Clinical Trial

Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism)

Pharmacodynamic Equivalence of Ramipril 10 mg and Atorvastatin 40 mg Administered as a Cardiovascular (CV) Polypill Acetylsalicylic Acid-Atorvastatin-Ramipril (AAR) as Compared to Monotherapy

Treatment of Supine Hypertension in Autonomic Failure

A Pharmacodynamic Study to Evaluate the Effect of a Fixed Dose Combination Pill on Blood Pressure

Pharmacokinetics of Elinogrel in Healthy Volunteers and Patients With Mild, Moderate, and Severe Renal Impairment

Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease